Avalo Therapeutics AVTX
NASDAQ AVTX
$12.26 -0.10 (-0.81%)
At close: Oct 21, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) EV to EBITDA (2017 - 2018)

Updated

Avalo Therapeutics' (AVTX) EV to EBITDA was 13.47 for Q2 2018, up 37.2% from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) EV to EBITDA (2017 - 2018) Analysis & Trends

Over the twelve months ended Jun 30, 2018, Avalo Therapeutics' EV to EBITDA came in at 10.76; for FY2017, it came in at 10.23.

  • Per Business Quant data, the three quarters before Q2 2018 came in at 9.82 (Q1 2018), 10.23 (Q4 2017) and 1.48 (Q3 2017).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Avalo Therapeutics 533.82 Mn -158.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 13.47
Mar 31, 2018 9.82
Dec 31, 2017 10.24
Sep 30, 2017 1.48
API Access

Avalo Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=AVTX&period=max&api_key=YOUR_API_KEY